by Robert Hayes Posted on April 29, 2023April 29, 2023 Wilmington’s Charles River Labs Named A Top Ten Massachusetts Company For Gender Equity Among Executive Leadership Read More
by Robert Hayes Posted on February 17, 2023February 17, 2023 Wilmington’s Charles River Laboratories & Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration Read More
by Robert Hayes Posted on February 2, 2023February 3, 2023 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Acquires SAMDI Tech For $50 Million Read More
by Robert Hayes Posted on June 28, 2022June 28, 2022 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Announces Opening of U.K. Manufacturing Facility Read More
by Robert Hayes Posted on April 10, 2022April 10, 2022 Wilmington’s Charles River Laboratories Acquires Explora BioLabs Read More
by Robert Hayes Posted on March 28, 2022March 28, 2022 Wilmington’s Charles River Laboratories To Appoint Flavia H. Pease As Chief Financial Officer Read More
by Robert Hayes Posted on July 3, 2021July 3, 2021 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Acquires Vigene Biosciences For $292.5 Million Read More
by Robert Hayes Posted on May 17, 2021May 17, 2021 BUSINESS BRIEF: Wilmington’s Charles River Labs To Acquire Vigene Biosciences To Enhance Gene Therapy Capabilities Read More
by Robert Hayes Posted on April 6, 2021April 6, 2021 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Completes Acquisition Of Cognate BioServices For $875 Million Read More
by Robert Hayes Posted on April 5, 2021April 5, 2021 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Acquires Retrogenix Read More
by Robert Hayes Posted on March 1, 2021February 28, 2021 BUSINESS BRIEF: Charles River Labs Announces Strategic Partnership With Kibur Medical To Advance Preclinical Oncology Studies Read More
by Robert Hayes Posted on February 21, 2021February 21, 2021 BUSINESS BRIEF: Wilmington’s Charles River Laboratories To Acquire Cognate BioServices For $875 Million Read More
You must be logged in to post a comment.